Payment overview · 2025
General Payments
$1,243.72
66 reported records · 21 companies
Healthcare provider profile · identity verified
Thomas D Bryan, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, SC · NPI 1073990511
Verified facts
What the public records show
CMS Open Payments records show Thomas D Bryan, MD received $1,243.72 in general payments during 2025 across 66 reported records.
ABBVIE INC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Nurtec Odt, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $288.66 | 23.2% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.71 | 13.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.97 | 7.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $79.51 | 6.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.99 | 6.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.87 | 5.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $55.73 | 4.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $55.68 | 4.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.62 | 4.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.51 | 3.3% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $38.75 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.33 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.09 | 2.5% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.20 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.60 | 2.0% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $23.80 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.47 | 1.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.40 | 1.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.11 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.23 | 1.5% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $16.49 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,243.72 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $146.02 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $142.64 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.10 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $128.10 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.17 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $105.23 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.87 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $55.73 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.62 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.55 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.55 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $38.75 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $38.75 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.22 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $29.60 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.07 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 409 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 333 | 92 |
| Omeprazole | Omeprazole | 321 | 87 |
| Lisinopril | Lisinopril | 284 | 83 |
| Gabapentin | Gabapentin | 247 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 229 | 33 |
| Losartan Potassium | Losartan Potassium | 219 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 64 |
| Prednisone | Prednisone | 202 | 158 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 52 |
| Furosemide | Furosemide | 182 | 60 |
| Metformin Hcl | Metformin Hcl | 175 | 54 |
| Famotidine | Famotidine | 172 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 42 |
| Tramadol Hcl | Tramadol Hcl | 154 | 49 |
| Bupropion Xl | Bupropion Hcl | 152 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 52 |
| Doxycycline Hyclate | Doxycycline Hyclate | 132 | 94 |
| Trazodone Hcl | Trazodone Hcl | 124 | 32 |
| Meloxicam | Meloxicam | 115 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 108 | 89 |
| Alprazolam | Alprazolam | 106 | 15 |
| Eliquis | Apixaban | 103 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 20 |
| Sertraline Hcl | Sertraline Hcl | 100 | 29 |
| Mounjaro | Tirzepatide | 98 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 20 |
| Clonazepam | Clonazepam | 94 | 19 |
| Montelukast Sodium | Montelukast Sodium | 93 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 27 |
| Pregabalin | Pregabalin | 90 | 25 |
| Glimepiride | Glimepiride | 89 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 22 |
| Simvastatin | Simvastatin | 77 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 21 |
| Ondansetron Odt | Ondansetron | 73 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 22 |
| Metformin Hcl Er | Metformin Hcl | 66 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 18 |
| Ezetimibe | Ezetimibe | 61 | 17 |
| Ibuprofen | Ibuprofen | 61 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 11 |
| Allopurinol | Allopurinol | 57 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 30 |
| Finasteride | Finasteride | 55 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 15 |
| Synthroid | Levothyroxine Sodium | 55 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 16 |
| Meclizine Hcl | Meclizine Hcl | 53 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 15 |
| Januvia | Sitagliptin Phosphate | 46 | 14 |
| Methocarbamol | Methocarbamol | 46 | 24 |
| Ozempic | Semaglutide | 46 | 11 |
| Potassium Chloride | Potassium Chloride | 46 | 12 |
| Diazepam | Diazepam | 45 | 14 |
| Lorazepam | Lorazepam | 45 | 12 |
| Promethazine Hcl | Promethazine Hcl | 43 | 18 |
| Alendronate Sodium | Alendronate Sodium | 42 | 13 |
| Carvedilol | Carvedilol | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 31 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 16 |
| Cephalexin | Cephalexin | 36 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 17 |
| Atenolol | Atenolol | 35 | 12 |
| Azithromycin | Azithromycin | 35 | 34 |
| Telmisartan | Telmisartan | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Topiramate | Topiramate | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 11 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Belsomra | Suvorexant | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Mometasone Furoate | Mometasone Furoate | 25 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Azelastine Hcl | Azelastine Hcl | 22 | 15 |
| Baclofen | Baclofen | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Primidone | Primidone | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Mupirocin | Mupirocin | 15 | 12 |
| Neupro | Rotigotine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,243.72 · 66 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AMS 700, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, Heplisav-B, IBSRELA, INJECTAFER, JARDIANCE, KRYSTEXXA, NURTEC ODT, OTEZLA, PREVNAR 20, PROLIA, QULIPTA, Quviviq, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYEPTI, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error